Maridebart cafraglutide
Maridebart cafraglutide (AMG 133) is an antibody-peptide conjugate acting as a GLP-1 receptor agonist and an antagonist of the GIP receptor. Maridebart cafraglutide reduces body weight and improve metabolic markers in male obese mice and cynomolgus monkeys. Maridebart cafraglutide is promising for research of obesity[1][2].
Product Specifications
CAS Number
2887445-76-1
Product Name Alternative
AMG 133
UNSPSC
12352203
Target
Antibody-Drug Conjugates (ADCs) ; GLP Receptor
Type
ADC Related
Related Pathways
Antibody-drug Conjugate/ADC Related; GPCR/G Protein
Applications
Metabolism-protein/nucleotide metabolism
Field of Research
Metabolic Disease
Assay Protocol
https://www.medchemexpress.com/maridebart-cafraglutide.html
Purity
99.24
Smiles
[Maridebartcafraglutide]
Molecular Weight
153,514 (average)
References & Citations
[1]Bloomgarden Z T. The 2023 WCIRDC: Obesity[J]. Journal of Diabetes, 2024, 16 (4) .|[2]Véniant MM, et al. A GIPR antagonist conjugated to GLP-1 analogues promotes weight loss with improved metabolic parameters in preclinical and phase 1 settings. Nat Metab. 2024 Feb;6 (2) :290-303.
Shipping Conditions
Dry Ice
Storage Conditions
-80°C, protect from light
Scientific Category
ADC Related
Clinical Information
Phase 1
Available Sizes
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
K1816105 3x 1.0 µg
RGPD5 sgRNA CRISPR/Cas9 All-in-One Lentivector set (Human)
Sign In for Pricing
View Details 
49398124 3x 1.0µg DNA
UTRN CRISPRa sgRNA lentivector (set of three targets)(Mouse)
Sign In for Pricing
View Details